Patient Access to Pulmolive in China

Published 20 Aug 2021
Reference 6138
Topic Marketing
Industry Pharmaceuticals
Region Asia

An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients. As the vast majority of patients in China would have to pay out of their own pocket, pricing the medicine at the international ex-factory price would make it unaffordable for many.

Teaching objectives

Pricing and access strategy for high-priced non-reimbursed new medicines:
- Medicine access barriers
- Affordability (ability-to-pay) analysis
- Inter-country and intra-(within)-country differential pricing

  • Pharmaceutical
  • Pricing
  • Differential pricing
  • Access to medicines
  • Affordability
  • Social responsibility
  • China
  • Cancer
  • Q32021